Search

KR-102963404-B1 - Composition improving, preventing or treating systemic sclerosis and pulmonary fibrosis comprising Bifidobacterium longum RAPO

KR102963404B1KR 102963404 B1KR102963404 B1KR 102963404B1KR-102963404-B1

Abstract

The present invention Bifidobacterium longum The present invention relates to a composition for improving, preventing, or treating systemic sclerosis and pulmonary fibrosis containing RAPO (KCTC13773BP) as an active ingredient, through which it can regulate inflammatory mononuclear cell and macrophage infiltration and inflammatory response, and promote the increase of microorganisms that produce short-chain fatty acids, thereby exhibiting an effect of improving, preventing, or treating systemic sclerosis and pulmonary fibrosis.

Inventors

  • 이상일
  • 박명수

Assignees

  • 경상국립대학교산학협력단
  • 주식회사 비피도

Dates

Publication Date
20260512
Application Date
20240313

Claims (8)

  1. delete
  2. Bifidobacterium longum A food composition for improving systemic sclerosis and pulmonary fibrosis containing RAPO (KCTC13773BP) as an active ingredient.
  3. delete
  4. Bifidobacterium longum A pharmaceutical composition for the prevention or treatment of systemic sclerosis and pulmonary fibrosis containing RAPO (KCTC13773BP) as an active ingredient.
  5. delete
  6. Bifidobacterium longum Animal food composition for improving systemic sclerosis and pulmonary fibrosis containing RAPO (KCTC13773BP) as an active ingredient.
  7. delete
  8. Bifidobacterium longum An animal medicine for the prevention or treatment of systemic sclerosis and pulmonary fibrosis containing RAPO (KCTC13773BP) as an active ingredient.

Description

Composition for improving, preventing, or treating systemic sclerosis and pulmonary fibrosis comprising Bifidobacterium longum RAPO as an active ingredient The present invention Bifidobacterium longum The present invention relates to a composition for improving, preventing, or treating systemic sclerosis and pulmonary fibrosis comprising RAPO (KCTC13773BP) as an active ingredient, and more specifically, to a composition having the efficacy to improve, prevent, or treat systemic sclerosis and pulmonary fibrosis through the anti-inflammatory and anti-fibrotic efficacy and mechanism of action of Bifidobacterium longum RAPO. Systemic sclerosis (SSc) is an autoimmune disease characterized by severe fibrosis of the skin and internal organs and vascular occlusion due to functional and structural abnormalities of small blood vessels. It is an intractable rare disease that causes serious complications such as pulmonary fibrosis and pulmonary hypertension. In particular, interstitial lung disease (ILD) is a representative complication associated with 55-80% of systemic sclerosis patients and is known to be the leading cause of mortality in patients with systemic sclerosis. Interstitial lung disease progresses into pulmonary fibrosis, which causes severe respiratory distress due to the excessive proliferation of fibroblasts during the process of lung tissue damage and inflammation. The most frequent form of pulmonary fibrosis is a form similar to idiopathic pulmonary fibrosis (IPF), the exact cause of which has not yet been identified, and it is an intractable disease in which lung tissue, once damaged, cannot be restored. Although the exact cause of systemic sclerosis is not yet known, inflammation, immune abnormalities, and vascular disease are considered important triggering factors, and recent studies suggest the microbiome as one of the pathogenic factors of systemic sclerosis. Previous studies have observed a decrease in microorganisms that produce butyrate, a type of short-chain fatty acid, in the intestines of patients with systemic sclerosis, and it has been confirmed that cutaneous and pulmonary fibrosis are inhibited after the administration of sodium butyrate, known as a microbial fermentation metabolite, in mice with systemic sclerosis and pulmonary fibrosis. As there are currently no effective treatments for systemic sclerosis and pulmonary fibrosis, and there is a high demand for the development of new therapies, it is necessary to develop new treatments that are effective and safe for the human body. Figure 1 is a graph showing the results of evaluating the fibrosis-inhibiting efficacy of Bifidobacterium strains in mice with systemic sclerosis (*P<0.05 vs PBS). Figure 2 shows Bifidobacterium longum in mice with systemic sclerosis disease. Graphs (A–C) showing the results of evaluating the therapeutic efficacy of RAPO (KCTC13773BP) for cutaneous and associated pulmonary fibrosis, and Bifidobacterium longum in mice with idiopathic pulmonary fibrosis Graphs (D~E) show the results of evaluating the therapeutic efficacy of RAPO (KCTC13773BP) for pulmonary fibrosis (*P<0.05, **P<0.01). Figure 3 shows a conventional pulmonary fibrosis treatment and Bifidobacterium longum in mice with idiopathic pulmonary fibrosis. This is a graph showing the results of evaluating the therapeutic efficacy of RAPO (KCTC13773BP) administered alone or in combination for pulmonary fibrosis (*P<0.05). Figure 4 shows Bifidobacterium longum in mice with systemic sclerosis disease. This is a graph confirming the pattern of inhibition of fibrosis marker protein expression by RAPO (KCTC13773BP) (*P<0.05, **P<0.01). Figure 5 shows Bifidobacterium longum in mice with systemic sclerosis disease. This is a graph showing the results of the analysis of macrophages in the skin (A) and the analysis of morphological changes in macrophages in bronchoalveolar fluid (B) using RAPO (KCTC13773BP) (*P<0.05, **P<0.01). Figure 6 shows Bifidobacterium longum in mice with systemic sclerosis disease. This is a graph showing the results of the analysis of inflammatory substance concentrations in bronchoalveolar fluid using RAPO (KCTC13773BP) (A), evaluation of fibrosis/inflammatory marker gene expression in skin and lung tissue (B), and analysis of inflammatory mononuclear cells in the spleen (C) (*P<0.05, **P<0.01). Figure 7 shows Bifidobacterium longum in mice with systemic sclerosis. This is a graph showing the results of the RAPO (KCTC13773BP) intestinal microbial diversity index evaluation (A) and changes in the intestinal microbial community distribution (B) (*P<0.05, **P<0.01). Figure 8 shows Bifidobacterium longum in mice with systemic sclerosis disease. This is a graph showing the relative distribution of microorganisms producing short chain fatty acids (SCFAs) in RAPO (KCTC13773BP) (*P<0.05, **P<0.01). Figure 9 shows Bifidobacterium longum in mice with systemic sclerosis disease. This is a graph showing the results of evaluating the expression of